<DOC>
	<DOCNO>NCT00589121</DOCNO>
	<brief_summary>RATIONALE : Image-guided radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers low dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase II trial study side effect well image-guided radiation therapy work treat patient primary soft tissue sarcoma shoulder , arm , hip , leg .</brief_summary>
	<brief_title>Image-Guided Radiation Therapy Treating Patients With Primary Soft Tissue Sarcoma Shoulder , Arm , Hip , Leg</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine effect reduce radiation volume use image-guided radiotherapy ( IGRT ) lymphedema ≥ grade 2 , subcutaneous fibrosis , joint stiffness 2 year patient primary soft tissue sarcoma extremity . Secondary - To estimate rate grade 3-5 adverse event measure Common Toxicity Criteria Adverse Effects ( CTCAE ) v3.0 . - To determine pattern first failure , include local failure ( in-field , marginal , outside-field failure ) , regional failure , distant failure , death without disease progression . - To estimate rate local failure , local-regional failure , distant failure , distant disease-free survival , disease-free survival , overall survival , second primary tumor . - To estimate rate wound complication . - To correlate degree late radiation morbidity ( define lymphedema , subcutaneous fibrosis , joint stiffness ) 2 year score clinical measure , Musculoskeletal Tumor Rating Scale ( MTRS ) . OUTLINE : This multicenter study . - Neoadjuvant radiotherapy : Patients assign 1 2 treatment group ( group 1 close accrual 01/08/10 ) . - Group 1 ( close accrual 01/08/10 ) : Patients undergo 3-D conformal radiotherapy ( 3D-CRT ) intensity-modulated therapy ( IMRT ) daily , 5 day week , 4½-5 week . Patients also receive 6 course neoadjuvant , adjuvant , concurrent , interdigitated chemotherapy . - Group 2 : Patients undergo 3D-CRT IMRT daily , 5 day week , 5 week . - Surgery : At 4-8 week completion neoadjuvant radiotherapy , patient undergo surgical resection tumor . Patients positive tumor margin ( residual tumor ) undergo intraoperative radiotherapy boost proceed adjuvant radiotherapy within 2 week surgery . - Adjuvant radiotherapy : Patients undergo either external-beam radiotherapy ( EBRT ) daily 8 fraction brachytherapy . After completion study treatment , patient follow least every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Radiation Pneumonitis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary soft tissue sarcoma upper extremity ( include shoulder ) low extremity ( include hip ) Incisional core biopsy require within past 8 week No histopathological diagnosis following : Rhabdomyosarcoma Extraosseous primitive neuroectodermal tumor ( PNET ) Soft tissue Ewing sarcoma Osteosarcoma Kaposi sarcoma Angiosarcoma Aggressive fibromatosis ( desmoid tumor ) Dermatofibrosarcoma protuberans Chondrosarcoma Extraskeletal myxoid chondrosarcoma allow Tumor must surgically resectable , determine surgeon within past 8 week Limbpreservation surgery alone would provide adequate local control , determine surgeon No sarcoma hand , foot , head , neck , intraabdominal retroperitoneal region body wall No sarcoma ≥ 32 cm direction No lymph node distant metastasis , accord follow within past 8 week : History/physical examination , include detailed description location , size , stage sarcoma MRI contrast primary tumor The maximum dimension primary tumor measure MRI image CT scan chest Multiple pulmonary nodule &lt; 8 mm without histological diagnosis detect incidentally nonscreening CT scan may allow CT scan contrast abdomen pelvis patient intermediate highgrade sarcoma upper thigh No recurrent tumor prior potentially curative therapy PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL ( transfusion intervention allow ) Bilirubin ≤ 1.5 mg/dL* Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2 time upper limit normal* Serum creatinine ≤ 1.6 mg/dL OR creatinine clearance ≥ 55 mL/min* Left ventricular ejection fraction ( LVEF ) ≥ 50 % multiple gated acquisition scan ( MUGA ) echocardiogram* Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy within past 3 year , except nonmelanomatous skin cancer carcinoma situ breast , oral cavity , cervix No severe , active comorbidity , include following* : Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial infection fungal infection require intravenous antibiotic Acquired Immune Deficiency Syndrome ( AIDS ) immunocompromised patient HIV test require No NCI CTCAE v 3.0 grade 34 electrolyte abnormality , include following* : Calcium &lt; 7 mg/dL &gt; 12.5 mg/dL Glucose &lt; 40 mg/dL &gt; 250 mg/dL Magnesium &lt; 0.9 mg/dL &gt; 3 mg/dL Potassium &lt; 3mmol/L &gt; 6 mmol/L Sodium &lt; 130 mmol/L &gt; 155 mmol/L NOTE : *Applies group 1 , close accrual 01/08/10 ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior excisional biopsy majority tumor ( ≥ 50 % ) remove No prior radiotherapy region study cancer would result overlap radiotherapy field No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>radiation fibrosis</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>lymphedema</keyword>
	<keyword>musculoskeletal complication</keyword>
	<keyword>stage I adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>adult extraskeletal chondrosarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
</DOC>